CTRI/2021/10/037416Not yet recruitingPhase 2
Subconjunctival injection of Bevacizumab (Anti VEGF) for Corneal Neovascularisation,after Penetrating Keratoplasty, A Prospective,Open Label,Non Comparative study
SNMedical College0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1)patients having 2 or more than 2 quadrant corneal neovascularisation
- •2)patients who developed corneal neovascularisation during F/U ,not responding to conventional medical treatment .
- •3)patients who gave consent to be in follow up.
Exclusion Criteria
- •1)patients having persistent epithelial defect
- •2)patients who were systemically not fit for subconj Bevacizumab injection;pts with H/O recent attack of M.I.,stroke and uncontrolled Hypertension.
- •3)pregnant female
Investigators
Similar Trials
Completed
Not Applicable
Intravitreal bevacizumab injection for intraocular neovascularization in childreRetinopathy of prematurityJPRN-UMIN000014316Kansai Medical University15
Completed
Not Applicable
The intravitreal injection of Bevacizumab for retinopathy of prematurityretinopathy of prematurityJPRN-UMIN000028770Department of Ophthalmology, Shiga University of Medical Science24
Not yet recruiting
Not Applicable
Intravitreal Bevaxizumab injection for intraocular neovasculalization in childreretinopathy of prematurityJPRN-UMIN000007465Tokushima university hospital10
Not yet recruiting
Not Applicable
Subtenon injection of bevacizumab for retinal vein occulusioretinal vein occulusionJPRN-UMIN000005254Department of Ophthalmology, Keio University School of Medicine40
Recruiting
Not Applicable
Treatment with bevacizumab for ocular vascular lesionsOcular vascular lesionsJPRN-UMIN000020916Keio University, School of Medicine1,000